Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1316 plus chemotherapy perioperative treatment in resectable esophageal squamous cell carcinoma
ChiCTR2300069179Phase 2Completed
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Mar 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Peking University Cancer Hospital & Institute. Primary endpoints: Safety and Pathologic complete response. Started Mar 2023; status: completed.
02
Drugs
adebrelimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2300069179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300069179.